Whitehawk Therapeutics Inc (WHWK) FinancialsWHWKFinancialWhitehawk Therapeutics Inc

Evaluating the bottom line, Whitehawk Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -68.54%, provide a clear picture of how effectively WHWK converts its operational activities into shareholder value.

In the context of the broader market, WHWK competes directly with industry leaders such as SRZN and SION. With a market capitalization of $277.63M, it holds a significant position in the sector. When comparing efficiency, WHWK's gross margin of N/A stands against SRZN's N/A and SION's N/A. Such benchmarking helps identify whether Whitehawk Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Whitehawk reported a gross margin of 89.36% in Q1 2025, indicating strong profitability potential despite recent losses. The company has a forward P/E ratio of 2.661, suggesting it may be undervalued compared to future earnings expectations.